Research Analysts Set Expectations for KPTI Q2 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Research analysts at HC Wainwright lowered their Q2 2026 earnings estimates for Karyopharm Therapeutics in a research report issued to clients and investors on Friday, July 31st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($1.38) for the quarter, down from their prior forecast of ($0.81). HC Wainwright has a “Neutral” rating and a $3.00 price objective on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($3.24) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q3 2026 earnings at ($1.05) EPS, Q4 2026 earnings at ($0.85) EPS and FY2026 earnings at ($4.10) EPS.

A number of other analysts have also recently commented on KPTI. Robert W. Baird cut shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research report on Friday. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st. Piper Sandler decreased their target price on Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research report on Friday. Weiss Ratings downgraded Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock opened at $1.97 on Tuesday. Karyopharm Therapeutics has a 52-week low of $1.80 and a 52-week high of $10.99. The firm has a 50 day moving average price of $8.75 and a two-hundred day moving average price of $8.15. The firm has a market cap of $44.64 million, a price-to-earnings ratio of -0.13 and a beta of 0.90.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.24) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.21. The firm had revenue of $35.07 million for the quarter, compared to analyst estimates of $31.40 million.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Avidity Partners Management LP boosted its stake in Karyopharm Therapeutics by 244.6% in the first quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after acquiring an additional 329,175 shares during the last quarter. Royal Bank of Canada lifted its stake in Karyopharm Therapeutics by 4.1% in the first quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock valued at $336,000 after purchasing an additional 2,399 shares during the last quarter. Commodore Capital LP purchased a new position in Karyopharm Therapeutics in the first quarter valued at approximately $10,862,000. OMERS ADMINISTRATION Corp bought a new position in Karyopharm Therapeutics during the first quarter valued at $108,000. Finally, Renaissance Technologies LLC lifted its position in shares of Karyopharm Therapeutics by 75.9% during the 1st quarter. Renaissance Technologies LLC now owns 105,414 shares of the company’s stock valued at $587,000 after buying an additional 45,500 shares during the last quarter. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.